Chronic migraine treated with SPG nerve block
For this study 41 patients were enrolled in two different headache speciality clinics in the US. They were between 18 – 80 years old and all of them had a history of chronic migraine. Throughout the study patients could take a stable amount of migraine medication. Patients went through a 28 day period of monitoring before starting treatment. After the 28 day period patients were randomly assigned to two groups by a computer generated list. One group received 0.5% bupivacaine and the other received 0.5% saline- an inactive/ neutral substance.
The drugs were administered through the insertion of a tube into the nasal passages, to the region surrounding the Sphenopalatine Ganglion. The drug was then released through the tube, into the region surrounding the Sphenopalatine Ganglion. This was done through both nostrils with 12 doses of 0.5% bupivacaine or saline 2 times per week for 6 weeks. Patients were assessed 1 and 6 months after the last procedure. Patients had to report their migraine experiences before treatment and 15 minutes, 30 minutes and 2 hours after treatment using a numeric scale.
Only 38 patients completed the study. 26 patients in the bupivacaine group and 12 in the saline group. Analyses of the data showed that the bupivacaine group had a significant decrease in scores compared to the saline group at all time points. Scores relating to the intensity of the headaches were also decreased in the bupivacaine group after treatment compared to before treatment. The saline group showed no difference in pain intensity scores before and after treatment.
Sphenopalatine Ganglion: The point at which the three branches of the trigeminal nerve converge. The trigeminal nerve sends and receives information about pain and sensation to the head and face. The Sphenopalatine Ganglion is found behind and below the eye.
Bupivacaine: Is a drug used to block the Sphenopalatine Ganglion.
View the original Sphenopalatine Ganglion Block migraine treatment at this link: A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine